Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - kasside leukeemia viiruse rekombinantse canarypox viirus (vcp97) - immunoloogilised ravimid jaoks felidae, - kassid - 8 nädala vanuste või vanemate kasside aktiivne immuniseerimine kasside leukeemia vastu püsiva viraemia ja selle haiguse kliiniliste tunnuste ennetamiseks. immuunsuse tekkimine on näidustatud 2 nädalat pärast esmast vaktsinatsioonikursust. immuunsuse kestus on üks aasta pärast viimast vaktsineerimist.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp65 viirus - immunoloogilised vahendid - kassid - 12-nädalaste ja vanemate kasside aktiivne immuniseerimine marutaudi nakkuse põhjustatud suremuse ärahoidmiseks. immuunsuse tekkimine: 4 nädalat pärast esmast vaktsineerimiskursust. immuunsuse kestus pärast esmast vaktsineerimist: 1 aasta. immuunsuse kestus pärast revaktsineerimist: 3 aastat.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. immuunsuse tagajärgi on tõestatud üks nädal pärast esmast vaktsinatsioonikursust rinotrahheiidi, kalitsiviiruse, chlamydophila felis ja panleukopeenia komponentide jaoks. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopa Liit - eesti - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunoloogilised ravimid jaoks felidae, - kassid - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. immuunsuse tekkekohad on tõestatud 1 nädala jooksul pärast esmast vaktsinatsioonikursust rinotrahheiidi, kalitsiviiruse ja chlamydophila felis komponentide jaoks. immuunsuse kestus on 1 aasta pärast viimast (uuesti) vaktsineerimist.

Eesti - eesti - Ravimiamet

auxilia pharma oÜ - minoksidiil - nahalahus - 50mg 1ml 60ml 1tk

Eesti - eesti - Ravimiamet

sanofi pasteur - poliomüeliidi koguviirus, trivalentne, inaktiveeritud - süstesuspensioon - 1annus 0.5ml 1annus 1tk